Pharmacokinetic and clinical considerations in the choice of a hypnotic.
Open Access
- 1 February 1983
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 16 (S1) , 5S-10S
- https://doi.org/10.1111/j.1365-2125.1983.tb02265.x
Abstract
Not only has insomnia become much more frequent in the last hundred years but its causes have also changed considerably. In the treatment of insomnia, benzodiazepines-because of their additional anxiolytic effect-offer substantial advantages over other sleep-inducing agents. The residual fraction-the quotient of plasma concentration at 12 h after drug intake to maximum plasma concentration-makes it possible to differentiate between the benzodiazepines according to their suitability as anxiolytics or hypnotics. Midazolam has the lowest residual fraction of all known benzodiazepines and thus, administered in the appropriate dosage, also has the shortest duration of activity.This publication has 7 references indexed in Scilit:
- Pharmacokinetics and bioavailability of midazolam in man.British Journal of Clinical Pharmacology, 1983
- [Pharmacokinetics of soporific drugs].1980
- Importance of Pharmacokinetic Data for Clinical PracticePublished by Springer Nature ,1980
- Pharmacokinetics of flunitrazepam following single- and multiple-dose oral administration to healthy human subjectsJournal of Pharmacokinetics and Biopharmaceutics, 1978
- Disposition of diazepam and its major metabolite desmethyldiazepam in patients with liver diseaseClinical Pharmacology & Therapeutics, 1977
- Bioavailability from various galenic formulations of flunitrazepam.1977
- Absorption and excretion of 7-chloro-1,3-dihydro-3-hydroxy-5-phenyl-2H-1,4-benzodiazepin-2-one (oxazepam) in humans. Determination of the drug by gas-liquid chromatography with electron capture detection.1972